[A21-27] Selpercatinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 15.06.2021
Project no.:
A21-27
Commission:
Commission awarded on 12.03.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC) who require systemic therapy
After first-line therapy with a PD-1/PD-L1 antibody as monotherapy: added benefit not proven.
After first-line therapy with cytotoxic chemotherapy: added benefit not proven.
After first-line therapy with a PD-1/PD-L1 antibody in combination with platinum-containing chemotherapy or after sequential therapy with a PD-1/PD-L1 antibody and platinum-containing chemotherapy: added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A21-28 | Selpercatinib (RET mutant medullary thyroid cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-29 | Selpercatinib (RET fusion-positive thyroid cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A24-62 | Selpercatinib (thyroid cancer) - Benefit assessment according to § 35a Social Code Book V | Commission completed |
| A24-63 | Selpercatinib (solid tumours) - Benefit assessment according to § 35a Social Code Book V | Commission completed |
| A22-106 | Selpercatinib (thyroid cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-65 | Selpercatinib (advanced NSCLC with RET fusion) – Benefit assessment according to § 35a SGB V | Commission completed |